Traws Pharma Enters Definitive Agreement, Completes Asset Deal
Ticker: TRAW · Form: 8-K · Filed: Sep 12, 2025 · CIK: 1130598
| Field | Detail |
|---|---|
| Company | Traws Pharma, Inc. (TRAW) |
| Form Type | 8-K |
| Filed Date | Sep 12, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $2,350,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: definitive-agreement, acquisition, disposition
TL;DR
Traws Pharma just closed a big deal and signed a definitive agreement. Big moves ahead.
AI Summary
Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) announced on September 9, 2025, the entry into a material definitive agreement and the completion of an acquisition or disposition of assets. The company is incorporated in Delaware and its principal business address is 12 Penns Trail, Newtown, PA 18940.
Why It Matters
This filing indicates significant corporate activity, potentially involving mergers, acquisitions, or divestitures, which could impact the company's structure and future operations.
Risk Assessment
Risk Level: medium — The filing indicates significant corporate actions like acquisitions or dispositions, which inherently carry strategic and financial risks.
Key Players & Entities
- Traws Pharma, Inc. (company) — Registrant
- Onconova Therapeutics, Inc. (company) — Former company name
- September 9, 2025 (date) — Date of earliest event reported
- 12 Penns Trail, Newtown, PA 18940 (location) — Business address
FAQ
What specific material definitive agreement did Traws Pharma, Inc. enter into?
The filing does not specify the details of the material definitive agreement, only that one was entered into on or before September 9, 2025.
What was the nature of the acquisition or disposition of assets?
The filing states that the completion of an acquisition or disposition of assets occurred, but does not provide details on the specific assets or the transaction.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this filing occurred on September 9, 2025.
What is Traws Pharma, Inc.'s former name?
Traws Pharma, Inc.'s former name was Onconova Therapeutics, Inc.
Where is Traws Pharma, Inc. incorporated and what is its business address?
Traws Pharma, Inc. is incorporated in Delaware and its business address is 12 Penns Trail, Newtown, PA 18940.
Filing Stats: 828 words · 3 min read · ~3 pages · Grade level 12.3 · Accepted 2025-09-12 16:33:58
Key Financial Figures
- $2,350,000 — ed Assets") from Viriom in exchange for $2,350,000 in cash (the "Purchase Price"), which w
Filing Documents
- tm2526017d1_8k.htm (8-K) — 28KB
- tm2526017d1_ex10-1.htm (EX-10.1) — 113KB
- 0001104659-25-089564.txt ( ) — 330KB
- tmb-20250909.xsd (EX-101.SCH) — 3KB
- tmb-20250909_lab.xml (EX-101.LAB) — 33KB
- tmb-20250909_pre.xml (EX-101.PRE) — 22KB
- tm2526017d1_8k_htm.xml (XML) — 3KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On September 9, 2025, Traws Pharma, Inc. (the "Company") and Virom, Inc. ("Viriom") entered into an Asset Purchase Agreement (the "Purchase Agreement"), pursuant to which the Company purchased certain assets (the "Purchased Assets") from Viriom in exchange for $2,350,000 in cash (the "Purchase Price"), which was paid in full to Virom on September 9, 2025. The Purchased Assets include certain intellectual property and other assets related to a pyrrolidine antiviral compound (the "Compound"), Viriom's program pipeline related thereto (the "Program") and any pharmaceutical product containing or comprising the Compound (a "Product"), including without limitation certain patents and patent applications; all other intellectual property controlled by Viriom related to the Program, Compound and Product; a third-party license agreement and rights and obligations related thereto; any and all material regulatory or similar filings, applications or associated correspondence related to the development, manufacture of commercialization of the Compound or product; all materials owned or controlled by Viriom related to the Program, Compound or Product; and certain other related assets. The Purchase Agreement contains customary representations, warranties and covenants. The Purchase Agreement also contains customary indemnification provisions by Viriom in favor of the Company. The foregoing description of the Purchase Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Purchase Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report and is incorporated herein by reference. Nikolay Savchuk, the Company's Chief Operating Officer, serves as Executive Chairman of Viriom. Additionally, Dr. Savchuk has investment control of Viriom and indirectly holds a significant number of its shares of common stock through a limited liability company of which Dr. Sav
01 Completion of Acquisition or Disposition of Assets
Item 2.01 Completion of Acquisition or Disposition of Assets. The information in Item 1.01 of this Current Report on Form 8-K (this "Current Report") regarding the Purchase Agreement and the transactions contemplated thereby is hereby incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1* Asset Purchase Agreement, dated September 9, 2025. 104 Cover Page Interactive Data File (embedded within the inline XBRL Document) * Certain annexes, schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant agrees to furnish supplementally a copy of any omitted attachment to the SEC on a confidential basis upon request.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 12, 2025 TRAWS PHARMA, INC. By: /s/ Iain Dukes Iain Dukes Interim Chief Executive Officer